New medicines for Lupus should also be tested in children with Lupus

Innovative new trial designs mean it will be possible to test new medicines in rare diseases such as childhood Lupus. Introduction Systemic lupus erythematosus (often called Lupus or SLE) is an autoimmune disease. It typically affects women between the ages of 15 and 45, but can start in younger children. There are many things that […]

Read More…

Recommendations for treat-to-target strategies in JIA

Expert guidance on general treatment approaches for children with juvenile idiopathic arthritis. INTRODUCTION Juvenile idiopathic arthritis, commonly referred to as JIA, is an umbrella term for a group of inflammatory arthritis conditions with unknown cause which begin in children before the age of 16. The types of arthritis that sit under this umbrella are shown […]

Read More…

Disease activity definitions do not always identify the same patients

Definitions of disease activity are important to help define and identify appropriate treatment plans, with the aim of achieving disease remission Introduction  Juvenile idiopathic arthritis is more commonly referred to as JIA, and includes most types of arthritis seen in children. JIA is a type of inflammatory arthritis that causes pain and swelling in one […]

Read More…

Moving young people with rheumatic diseases from paediatric to adult care

Introduction Recommendations give advice to doctors, other health professionals, patients and their families about the best way to treat and manage diseases. EULAR has written recommendations in partnership with Pediatric Rheumatology European Society (PReS) on the transitional care of young people with rheumatic diseases. Transitional care means moving young people from their childhood paediatric healthcare […]

Read More…